The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability. These revisions help to show the ever-changing nature of near-term business trends. Investors might also notice recent changes to analyst estimates for Novartis. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $6.98 per share and a revenue of $53.07 billion, indicating changes of +14.43% and +4.99%, respectively, from the former year. Meanwhile, the latest consensus estimate predicts the revenue to be $13.54 billion, indicating a 7.96% increase compared to the same quarter of the previous year. The company's upcoming EPS is projected at $1.77, signifying a 12.03% increase compared to the same quarter of the previous year. The company's earnings report is set to go public on October 24, 2023. ![]() The drugmaker's stock has dropped by 1.36% in the past month, exceeding the Medical sector's loss of 4.14% and the S&P 500's loss of 2.35%.Īnalysts and investors alike will be keeping a close eye on the performance of Novartis in its upcoming earnings disclosure. ![]() Elsewhere, the Dow saw a downswing of 0.51%, while the tech-heavy Nasdaq depreciated by 0.63%. This move lagged the S&P 500's daily loss of 0.63%. In the latest trading session, Novartis (NVS) closed at $97.87, marking a -1.55% move from the previous day.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |